Trial
NCT04847141
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Grifols Therapeutics LLC
Collaborators
—
Condition
COVID-19
Intervention
C19-IG 20%
Why stopped
Study Stopped for Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-05